# Safety and Performance of the Glyconics-SX System

Study · id `cardio:ct-nct05198895` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05198895](<https://clinicaltrials.gov/study/NCT05198895>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05198895

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT05198895. Allocation not applicable; no masking; primary purpose screening. Start 2022-08-01 (actual); primary completion 2022-10-19 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose screening
- Phase: Not applicable
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT05198895, source copy `cardio:ctgov-nct05198895-2023-10-23`, retrieved 2026-10-26)
- Started: 2022-08-01 (actual) (ClinicalTrials.gov record NCT05198895, source copy `cardio:ctgov-nct05198895-2023-10-23`, retrieved 2026-10-26)
- Primary completion: 2022-10-19 (actual) (ClinicalTrials.gov record NCT05198895, source copy `cardio:ctgov-nct05198895-2023-10-23`, retrieved 2026-10-26)
- Completion: 2022-10-28 (actual) (ClinicalTrials.gov record NCT05198895, source copy `cardio:ctgov-nct05198895-2023-10-23`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT05198895, source copy `cardio:ctgov-nct05198895-2023-10-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05198895-2023-10-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Performance of the Glyconics-SX System
- Acronym: ANODE01
- Condition: Diabetes Mellitus, Type 2
- Intervention (Device): Near-infrared (NIR)
- Lead sponsor: Glyconics Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 4ad36e9af6629e02a0dc57ccc11ca10c0f18863d1600595f3b2fb620ec84a1c9
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
